EN DE
Watch Fielmann Aktiengesellschaft for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Fielmann Aktiengesellschaft (FIE) fair value: what the stock is really worth

As of Nov 12, 2026: fair value (intrinsic value) of Fielmann Aktiengesellschaft stock €53.39, price €43.25, upside +23.4%, quality 64 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare DE · ISIN DE0005772206

FA Fielmann Aktiengesellschaft logo Broad data Nov 12, 2026

Fielmann Aktiengesellschaft

FIE · XETRA

Solid company, but only slightly cheap (19% below fair value) and falling price: meets 1 of 3 rules.

Get notified free when this changes
Fair value €53.39 · Undervalued 
Quality 64/100 
Healthy Growth (revenue 5y +11.3 %/yr in EUR) 
Low debt 
Generates free cash flow 
3.2% dividend yield · Well covered
Ranks above peers (11/15) 
Recent news very positive 
Broad data 
Thin margins · 8.6% net margin (TTM) 
Moderate moat 58/100 · thin data
Falling price (downtrend) 

Main risks:

🚩US margin slip from optometrist capacity investments
Watch Fielmann Aktiengesellschaft for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€56.46 €25.43 Fair Value €53.39 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.

How to read this chart

60‑month range €25.43 – €56.46 · fair‑value band €40.04 – €66.73 · the €43.25 price screens below the €53.39 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.

Follow Fielmann Aktiengesellschaft in your weekly email

Every Wednesday you see whether Fielmann Aktiengesellschaft is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Fielmann Group AG engages in vision care and audiology business in Germany, Switzerland, Austria, Spain, North America, and internationally.

Show moreShow less

The company manufactures and sells visual aids mainly glasses, eyewear frames and lenses, sunglasses, contact lenses, ready-made reading glasses, hearing systems and its accessories, as well as personal protective equipment.

It also offers its products under the fielmann, Optika Clarus, Optica & Audiologia Universitaria, Medical optica audicion, Shopko Optical, and SVS VISION brand names. The company sells its products through digital sales, retail stores, as well as Befitting, an optical e-commerce platform.

The company was formerly known as Fielmann Aktiengesellschaft and changed its name to Fielmann Group AG in July 2023. Fielmann Group AG was founded in 1972 and is headquartered in Hamburg, Germany. Fielmann Group AG operates as a subsidiary of Korva SE.

Stock analysis

Fielmann Aktiengesellschaft (FIE) currently trades at €43.25, while our model-based Fair Value estimate is €53.39, implying the stock looks roughly 19% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of €73.77 per share, and 15 of the 26 models we run sit above the €43.25 price.

Bear case: the Dividend Discount group reads lowest at €21.40, and 11 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: €40.04 (bear) to €66.73 (bull), the price of €43.25 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Fielmann Aktiengesellschaft reported revenue of €2.4B in FY2025 versus €1.7B in FY2021, a compound +9.8%/yr. Reported net income was €204M in FY2025, compounding +10.5%/yr from FY2021.

Key figures

Market cap €3.6B Mid · P/E ratio 16.6 · P/S ratio 1.45 · EPS (TTM) €2.60 · Dividend yield 3.2% · Net margin 8.6% · Return on equity 20.1% · Return on assets (EBIT) 18.4% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (low confidence).

What moves the price

The share trades about 6% below its 52-week high and 18% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −43% fair-value upside, at 23%, FIE screens cheaper than that median.

Fair Value models

Bear €40.04 Fair Value €53.39 Bull €66.73
Price €43.25 · Upside +23.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€1.04 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF €53.55 €85.10 €135.14 79
Growth DCF €54.72 €82.95 €125.11 78
Owner Earnings €51.45 €81.78 €129.88 75
All 26 models by family
DCF Models
FCF DCF €53.55 €85.10 €135.14 79
Owner Earnings €51.45 €81.78 €129.88 75
5Y Revenue Exit €39.78 €61.08 €87.83 72
5Y EBITDA Exit €58.45 €95.89 €139.34 74
5Y P/E Exit €41.23 €63.80 €87.14 71
10Y Revenue Exit €43.01 €63.84 €91.04 67
10Y EBITDA Exit €56.25 €88.46 €131.05 68
10Y P/E Exit €45.07 €65.76 €90.50 64
Earnings-Based
Graham-Dodd €16.50 €50.40 €66.90 65
Lynch FV €18.29 €26.13 €33.97 61
PEG = 1.0 €18.29 €26.13 €33.97 57
EPV €27.46 €32.39 €36.77 74
Dividend Discount
Gordon GGM €11.14 €24.20 €40.44 65
DDM Multi-Stage €11.14 €18.59 €25.24 66
Multiples
P/E Multiple €40.04 €53.39 €66.73 63
P/S Multiple €30.94 €41.25 €51.57 58
P/B Multiple €12.27 €16.37 €20.46 55
EV/EBIT €41.25 €57.63 €74.01 66
EV/EBITDA €61.32 €84.39 €107.46 67
EV/Revenue €27.19 €42.22 €57.25 53
Asset-Based
NCAV (Graham) €1.82 €2.44 €3.64 54
Growth DCF
Growth DCF €54.72 €82.95 €125.11 78
Rev-Margin DCF €39.78 €61.46 €86.39 72
Economic Profit
Residual Income €15.39 €19.50 €31.65 74
ROIC Compounder €29.50 €37.69 €47.22 72
Growth Earnings
Growth-Adj P/E €32.74 €46.77 €60.80 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 64/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 56
How much profit the company makes from its sales and capital
Quality Growth 40
Are margins and returns getting better?
Cashflow 75
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 59
Does it invest with discipline instead of growing at any price?
Low Volatility 85
How calm the share price moves, does not count
Price momentum 38
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 52
Distance to the 52-week high, does not count
New shares 87
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 89/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+7.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.3%
Start year 2020 (pandemic). Over 10 years: +6.5% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.9%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ +7.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.7%
Dividend (yield on the price)3.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.8.3% vs 2.1%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 13%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Rate on operating basis: 2025 sits 60% above its own trend.

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−5.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about −7.1% a year for the price and +2.4% for the forecasts.
Forecast 2026 (sales)+3.4%
Forecast 2027 (sales)+5.6%
Projected 2028 (sales)+5.2%
Projected 2029 (sales)+4.7%
Projected 2030 (sales)+4.3%

Watch FIE, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (48 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Note from the team Nov 10, 2026
AI conclusion: Fielmann benefits from rapid store openings and price leadership that boost sales growth in Germany and international markets, yet faces ongoing margin pressure in the US from investments in optometrist capacity.
Main risk: Margin pressure from investments in US optometrist capacity and business-model changes risks eroding profitability if added volumes and network reach fail to compensate.
Fielmann stepped up its price leadership with targeted reductions and kept opening new stores at a faster pace, which helped lift third-quarter sales growth and brought Germany back into positive territory. International markets continued to expand while the US margin slipped due to investments in optometrist capacity and business-model changes. Our models see the shares as undervalued. Will the added volumes and network reach offset the margin pressure from the US push before the next slowdown?
Join the discussion →

Compare Fielmann Aktiengesellschaft with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 196 stocks

Beats the industry median on 11/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 64 · Above median
Fair Value upside +23.4% · Top 25%
Profitability
Return on equity (12 months) 20.1% · Top 25%
Return on assets 7.6% · Above median
Net margin (12 months) 8.6% · Above median
Operating margin (12 months) 13.7% · Above median
Growth and dividend
Revenue growth (quarter YoY) 4.7% · Below median
Dividend yield (12 months) 3.2% · Top 25%
Balance sheet
Debt / equity 0.28× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (12 months) 16.6× · Cheaper than median
P/B 3.67× · Pricier than median
P/S (12 months) 1.45× · Cheaper than median
Price / free cash flow (fiscal year) 10.2× · Cheapest 25%
EV/EBITDA 8.2× · Cheaper than median
PEG 3.20× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)65 · sector 19
FUTURE (revenue growth)24 · sector 39
PAST (return on equity)80 · sector 27
HEALTH (low debt)86 · sector 96
DIVIDEND (yield)65 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $88.81 $131.27 +48% vs FIE
EssilorLuxottica Société anonyme EL €179.90 €196.22 +9% vs FIE
Intuitive Surgical, Inc ISRG $439.89 $353.90 −20% vs FIE
Medline Inc MDLN $39.98 $28.59 −28% vs FIE
Alcon Inc ALC CHF 60.28 CHF 34.29 −43% vs FIE
Becton, Dickinson and Company BDX $215.71 $97.80 −55% vs FIE
Straumann Holding STMN CHF 107.25 CHF 45.50 −58% vs FIE
West Pharmaceutical Services, Inc WST $411.30 $139.22 −66% vs FIE
Sartorius Stedim Biotech S.A DIM €222.80 €54.82 −75% vs FIE
Sartorius Aktiengesellschaft SRT €226.50 €46.44 −80% vs FIE

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Fielmann Aktiengesellschaft: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Fielmann Aktiengesellschaft Fair Value". https://www.fairvalue-calculator.com/stock/FIE

Frequently asked questions

Is Fielmann Aktiengesellschaft (FIE) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of €53.39 versus a price of €43.25, about +23% upside (undervalued).
What is the fair value of FIE?
Our model-based fair value for Fielmann Aktiengesellschaft is €53.39 (as of Nov 12, 2026), built from audited fundamentals. The current price: €43.25.
What is the quality score of FIE?
Fielmann Aktiengesellschaft has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fielmann Aktiengesellschaft (FIE)?
Our model-based price target is the fair value of €53.39 (as of Nov 12, 2026) from 26 valuation models. Cautious scenario €40.04, optimistic scenario €66.73. It is a calculation from audited fundamentals, not an analyst target.
What is the Fielmann Aktiengesellschaft stock forecast for 2026?
Our models put fair value at €53.39, about +23% upside versus a price of €43.25 (undervalued). Cautious scenario €40.04, optimistic scenario €66.73. The calculation is refreshed regularly with new filings.
What is the revenue of Fielmann Aktiengesellschaft (FIE)?
Fielmann Aktiengesellschaft reported trailing-twelve-month revenue of about €2.5B (latest available figure, as of Nov 12, 2026).
Does Fielmann Aktiengesellschaft pay a dividend?
Fielmann Aktiengesellschaft currently shows a dividend yield of 3.24% relative to its recent price (as of Nov 12, 2026).
How much is the dividend of Fielmann Aktiengesellschaft (FIE) and when is the ex-dividend date?
Fielmann Aktiengesellschaft pays a dividend of €1.40 per share a year, a dividend yield of 3.2%. The last ex-dividend date was Jul 10, 2026. A dividend has been paid every year since at least 1995. The payout ratio is 53.8% of earnings. Free cash flow covers the dividend 2.99 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Fielmann Aktiengesellschaft (FIE)?
For today's price to be fair in a discounted-cash-flow model, Fielmann Aktiengesellschaft would have to grow free cash flow by -5.1 % per year for five years (discount rate 8.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.3 % per year. As of Nov 12, 2026.
What discount rate (WACC) does the fair value of FIE use?
Our models discount Fielmann Aktiengesellschaft at 8.6 %: a base by market capitalisation (mid), damped by beta 0.60, country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Fielmann Aktiengesellschaft that is -5.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.6 %) and the same formula as our fair value.
How much growth has Fielmann Aktiengesellschaft (FIE) delivered so far?
Over the past 5 years revenue at Fielmann Aktiengesellschaft grew +11.3 % a year. The price currently implies free-cash-flow growth of -5.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Fielmann Aktiengesellschaft (FIE) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Fielmann Aktiengesellschaft (-5.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Fielmann Aktiengesellschaft (FIE)?
The free-cash-flow yield on the price is 9.77 %: that much free cash flow Fielmann Aktiengesellschaft produces per unit of market value. When it exceeds the discount rate of our models (8.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Fielmann Aktiengesellschaft (FIE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fielmann Aktiengesellschaft it is €53.39 per share (as of Nov 12, 2026), against a price of €43.25. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Fielmann Aktiengesellschaft stock overvalued or undervalued in 2026?
As of Nov 12, 2026, FIE trades below its calculated fair value: price €43.25, fair value €53.39, a gap of about +23% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FIE?
No. The price is what the market pays today (€43.25); the fair value is what the company's own numbers justify (€53.39). For Fielmann Aktiengesellschaft the two are €10.14 per share apart. That gap is exactly why we show both numbers side by side.
How much is Fielmann Aktiengesellschaft worth?
The market values Fielmann Aktiengesellschaft at about €3.6B (market capitalisation, as of Nov 12, 2026). Per share that is €43.25; our models calculate a fair value of €53.39 per share.
What do the bullish and bearish scenarios say about FIE?
Our models span a range for Fielmann Aktiengesellschaft: cautious scenario €40.04, base €53.39, optimistic €66.73 per share (as of Nov 12, 2026, price €43.25). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of FIE?
Fielmann Aktiengesellschaft trades at a price-to-earnings ratio of 16.6 (as of Nov 12, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €53.39 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 31.9. Other multiples: PEG 3.2, P/B 3.7, P/S 1.5, EV/EBITDA 8.2.
What is the PEG ratio of FIE?
The PEG ratio of Fielmann Aktiengesellschaft is 3.20 (P/E divided by earnings growth, as of Nov 12, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Fielmann Aktiengesellschaft (FIE)?
Balance-sheet figures for Fielmann Aktiengesellschaft (as of Nov 12, 2026): return on equity 20.1%, debt of 0.28 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is FIE from its 52-week high?
Fielmann Aktiengesellschaft trades at €43.25, about 6% below its 52-week high of €46.07 and 18% above the low of €36.75 (as of Nov 12, 2026). Distance from the high says nothing about value: that is what the fair value of €53.39 is for.
Which stocks are comparable to Fielmann Aktiengesellschaft?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fielmann Aktiengesellschaft stock attractive at the current price?
The data as of Nov 12, 2026: price €43.25, calculated fair value €53.39 (+23%), Quality Score 64/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FIE calculated?
We run Fielmann Aktiengesellschaft through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €53.39 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.3% above its aggregate fair value. Fielmann Aktiengesellschaft currently trades 19% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Fielmann Aktiengesellschaft (FIE)?
The closing price on Nov 12, 2026 was €43.25. Our model-based fair value is €53.39, about +23% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Fielmann Aktiengesellschaft right now?
Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Fielmann Aktiengesellschaft (FIE) come from?
Earnings per share at Fielmann Aktiengesellschaft grew −0.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.3 %, EBIT margin −3.9 %, tax rate −0.2 %, residual (interest, one-offs) −2.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Fielmann Aktiengesellschaft

How large is the market capitalisation of Fielmann Aktiengesellschaft (FIE)?
The market capitalisation of Fielmann Aktiengesellschaft is €3.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Fielmann Aktiengesellschaft (FIE)?
The price-to-sales ratio of Fielmann Aktiengesellschaft is 1.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Fielmann Aktiengesellschaft (FIE)?
Earnings per share at Fielmann Aktiengesellschaft are €2.60 (price ÷ EPS = P/E 16.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Fielmann Aktiengesellschaft (FIE)?
The dividend yield of Fielmann Aktiengesellschaft is 3.2% (payout 53.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Fielmann Aktiengesellschaft (FIE)?
The net margin of Fielmann Aktiengesellschaft is 8.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Fielmann Aktiengesellschaft (FIE)?
The return on equity (ROE) of Fielmann Aktiengesellschaft is 20.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Fielmann Aktiengesellschaft (FIE)?
On an EBIT basis the return on assets of Fielmann Aktiengesellschaft is 18.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Fielmann Aktiengesellschaft (FIE)?
The operating margin of Fielmann Aktiengesellschaft is 13.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Fielmann Aktiengesellschaft (FIE)?
Revenue at Fielmann Aktiengesellschaft is growing +4.7% versus a year earlier (3y avg +11.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Fielmann Aktiengesellschaft (FIE)?
Earnings per share at Fielmann Aktiengesellschaft are growing +11.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Fielmann Aktiengesellschaft (FIE) carry?
The net debt of Fielmann Aktiengesellschaft is €662M (fiscal year 2025, ≈ 1.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Fielmann Aktiengesellschaft in the live analysis

One click puts Fielmann Aktiengesellschaft on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.